secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2025-11-07T23:59:59+00:00
Accession:  0001104659-25-108154
Event type: regulatory
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA extends review of Rhythm's setmelanotide sNDA to March 20, 2026
-------------------------------------------------------------------

- New PDUFA goal date March 20, 2026, extended 3 months from December 20, 2025.
- FDA requested additional sensitivity analyses of Phase 3 efficacy data; no new data required.
- Major amendment classified; no safety or manufacturing issues included in the extension.
- Company expresses confidence in data and continues preparations for potential launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000110465925108154/0001104659-25-108154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000110465925108154/rytm-20251106x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-108154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer